Interventional research with low risks and constraints, prospective and monocentric on the assessment of long-term fertility in patients who underwent an adjuvant sequential chemotherapy with or without a controled ovarian hyperstimulation. This study follows a previous one called NCT 01614704.
The patients will have a follow-up once a year during ten years beginning at the end of their chemotherapy. They will have a consultation in oncology consisting of: * a clinical exam, * a collection and follow-up of oncological data * a collection of ongoing cancer treatments and a consultation in gynecology consisting of: * a pelvic ultrasound scan (for AFC: Antral Follicle Count) * a biological test (FSH, LH, E2, AMH) * a collection of gynecological data, contraception and reproductive medicine
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
132
Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
Blood test: * FSH, LH, E2 and AMH * 4 tubes of 7 mL
Antral Follicles Count
Centre Oscar Lambret
Lille, France
Assessment of fertility in terms of cumulative incidence of long-term pregnancy
for patients who underwent adjuvant sequential chemotherapy of anthracycline and taxane separately, depending on whether or not they have had Controlled Ovarian Hyperstimulation
Time frame: 10 years after chemotherapy
Assessment of fertility in terms of cumulative incidence of births
separately, depending on whether or not they have had Controlled Ovarian Hyperstimulation
Time frame: 10 years after chemotherapy
Assessment of fertility - number of pegnancies spontaneous versus assisted
describing the pregnancy type - number of pegnancies spontaneous versus assisted, with ot without the use of frozen gametes)
Time frame: 10 years after chemotherapy
Assessment of fertility - pregnancy outcome : miscarriage or single or multiple birth separately
describing the pregnancy outcome : miscarriage or single or multiple birth separately, depending on whether or not they have had Controlled Ovarian Hyperstimulation
Time frame: 10 years after chemotherapy
Assessment of the number of patient willing to re-exploit their frozen gametes
for patients who have had Controlled Ovarian Hyperstimulation
Time frame: 10 years after chemotherapy
Assessment of the gonadotoxicity of the adjuvant sequential chemotherapy based on anthracyclines and taxanes - AMH rate
in terms of AMH rate depending on whether or not they have had Controlled Ovarian Hyperstimulation
Time frame: 10 years after chemotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Assessment of the gonadotoxicity of the adjuvant sequential chemotherapy based on anthracyclines and taxanes - Antral Follicle Count
in terms of Antral Follicle Count depending on whether or not they have had Controlled Ovarian Hyperstimulation
Time frame: 10 years after chemotherapy
Study the long-term carcinologic safety of Controlled Ovarian Hyperstimulation without Letrozole or Tamoxifen co-treatment in terms of survival without relapse
Survival without relapse defined by the time frame between the date of surgery and the date of the first recurrence
Time frame: After chemotherapy ad until disease progression or death regardless of the cause, up to 10 years after chemotherapy